Market Research Logo

Europe Molecular Diagnostics Market Analysis By Product (Instruments, Reagents), by Test Location (Point of Care, Self-Test, Central Laboratories), by Technology (PCR, (Multiplex PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technolog


Europe Molecular Diagnostics Market Analysis By Product (Instruments, Reagents), by Test Location (Point of Care, Self-Test, Central Laboratories), by Technology (PCR, (Multiplex PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips & Microarrays, Mass Spectrometry, Sequencing, Transcription-mediated Amplification), by Application, Pharmacogenomics, Infectious Diseases Neurological Disease, Cardiovascular Disease,Microbiology), And Segment Forecasts to 2024

The europe molecular diagnostics market is expected to reach USD4.0 billion by 2024, according to a new report by Grand View Research, Inc. Growing geriatric population and the increasing prevalence of neurological and cardiovascular disorders is expected to drive the growth of molecular diagnostics. Moreover, increasing demand for more efficient healthcare delivery to facilitate early diagnostics is further expected to boost market growth.

Rising awareness levels among individuals pertaining to the availability of effective molecular diagnostic tests to determine the presence of genetic disorders is expected to increase the client base for this industry, consequently leading to early diagnosis of disorders in the population.

In addition, with the demand for high levels of accuracy and cost effectiveness of diagnostic procedures, the existent technologies are continually undergoing progressive changes to develop improved and efficient testing tools. Presence of a number of established healthcare facilities coupled with the technological advancements facilitating and expediting accurate disease diagnosis are expected to serve this market as significant drivers fueling growth.

Further key findings from the study suggest:

The overall vertical was dominated by the reagents with their revenue generation estimated at over USD 930.0 million in 2015 owing to their higher usage including formamide, salts, and dextran sulphate or heparin employed in the drug development process to detect disease-related novel biomarkers

Introduction of reagents for technologically advanced instruments are anticipated to attribute towards an attractive growth of reagents segment over the forecast period

Central laboratories held the largest market share of around 60% in 2015 owing to the highly developed healthcare infrastructure and skilled healthcare professionals & staff associated with them.

Point of care is the fastest growing test location segment with an estimated CAGR of over 12.0% over the forecast period. Increasing demand for expedited diagnosis and rapid analysis has led to the growth of this section.

Infectious diseases dominated the market on the basis of application with the largest revenue contribution in 2015 owing to the large test volumes and extensive portfolio of commercialized products in this area.

HIV held the largest market share of around 14.0% in 2015 in the infectious disease segment. Government initiatives being undertaken in Italy and France to create higher awareness about infectious diseases, such as HIV/AIDS and Hepatitis B, are factors responsible for its high market share.

Polymerase chain reaction (PCR) technology dominated the vertical with overall market revenue of over USD 725.0 million, attributable to the increasing application of molecular diagnostics in the field of drug discovery & development and pharmacogenomics

DNA sequencing is estimated to emerge as a profitable market over the forecast period with a CAGR of around 15.0%. With the sweeping technological advancements in the field, DNA sequencing is presently one of the most cost-effective technologies used to decode the genetic cause underlying a range of diseases.

The next generation sequencing technology segment will witness the highest growth rate throughout the forecast period majorly owing to the increasing R&D initiatives for development of novel drugs.

Germany held the largest market share with maximum revenue generation in 2015, which is attributed primarily to its huge elderly population base. Growing geriatric population coupled with decreased immune levels would engender the widespread prevalence of chronic diseases conditions comprising cardiovascular, neurological, and diabetes

The molecular diagnostics sector in the UK is estimated to grow at a faster rate with a CAGR of over 11.0% throughout the forecast period. The presence of sophisticated healthcare infrastructure, higher disposable income, and the increasing R&D intensity are the key factors contributing towards the growth of this sector in the UK.

Some leading companies in the molecular diagnostics sector include Roche Diagnostics, Alere Inc., Cepheid, Hologic, Inc. (Gen Probe), Sysmex Corporation, Abbott Laboratories, Bayer AG, Siemens Healthcare GmbH, Becton, Dickinson and Company, Johnson & Johnson, bioMérieux SA, Dako, Novartis AG (Grifols), Danaher Corporation, Bio-Rad Laboratories, Inc., and Qiagen N.V.

The established players in this vertical are adopting strategies, such as mergers and acquisitions, new product development, expansion activities pertaining to R&D of novel diagnostic products, and strategic collaborations to widen their existent product portfolios

Grand View Research has segmented the Europe molecular diagnostics market on the basis of product, technology, applications, test location, and country:

Europe Molecular Diagnostics Product Outlook (Market Revenue in USD Million, 2013 - 2024)

Instruments

Reagents

Others

Europe Molecular Diagnostics Test Location Outlook (Market Revenue in USD Million, 2013 - 2024)

Point of care

Self-testing or OTC

Central laboratories

Europe Molecular Diagnostics Technology Outlook (Market Revenue in USD Million, 2013 - 2024)

PCR

In-situ hybridization

Isothermal Nucleic Acid Amplification Technology (INAAT)

Chips and microarrays

Mass spectrometry

Sequencing

Transcription-mediated amplification

Others

Europe Molecular Diagnostics PCR, by segments Outlook (Market Revenue in USD Million, 2013 - 2024)

Multiplex PCR

Others

Europe Molecular Diagnostics Application Outlook (Market Revenue in USD Million, 2013 - 2024)

Oncology

Pharmacogenomics

Infectious diseases

Genetic testing

Neurological diseases

Cardiovascular diseases

Microbiology

Others

Europe Molecular Diagnostics Oncology, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)

Breast Cancer

Prostate Cancer

Colorectal Cancer

Cervical Cancer

Kidney Cancer

Liver Cancer

Blood Cancer

Lung Cancer

Others

Europe Molecular Diagnostics Infectious Disease, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)

Methicillin-resistant Staphylococcus aureus (MRSA)

Clostridium difficile

Vancomycin-resistant enterococci

Carbapenem-resistant bacteria testing

Flu

Respiratory syncytial virus (RSV)

Candida

Tuberculosis and drug-resistant TB

Meningitis

Gastro-intestinal panel testing

Chlamydia

Gonorrhea

HIV

Hepatitis C

Hepatitis B

Other

Europe Molecular Diagnostics Genetic Testing, By Application Outlook (Market Revenue in USD Million, 2013 - 2024)

Newborn screening

Predictive and presymptomatic testing

Others

Europe Molecular Diagnostics Country Outlook (Market Revenue in USD Million, 2013 - 2024)

UK

Germany

France

Spain

Italy

Belgium

Switzerland

Netherlands

Poland

Austria

Greece

Sweden

Turkey

Finland


Chapter 1 Executive Summary
Chapter 2 Europe Molecular Diagnostics - Industry Outlook
2.1 Introduction
2.2 Market Segmentation
2.3 Market Size and Growth Prospects
2.4 Molecular Diagnostics - Market dynamics
2.4.1 Market Driver Analysis
2.4.1.1 Growing geriatric population base
2.4.1.2 Introduction of technological advancements
2.4.1.3 Increasing demand for point of care facilities
2.4.1.4 Growing prevalence of target diseases such as hospital acquired infections, genetic, and cardiovascular &neurological diseases
2.4.1.5 External funding for executing research and development activities
2.4.2 Market Restraint Analysis
2.4.2.1 Presence of an ambiguous regulatory framework
2.4.2.2 High prices of molecular diagnostic tests
2.5 Key Opportunities Prioritized
2.6 Molecular Diagnostics - PESTEL Analysis
2.7 Molecular Diagnostics Market - Company Market Share Analysis, 2013
2.7.1 Recommendations for market participants
Chapter 3 Europe Molecular Diagnostics Product Outlook
3.1 Molecular Diagnostics Revenue Share, by Product, 2013 & 2024
3.2 Molecular Diagnostic Instruments Market
3.2.1 Molecular diagnostic instruments market, 2013 - 2024 (USD Million)
3.3 Molecular Diagnostic Reagents Market
3.3.1 Molecular diagnostic reagents market, 2013 - 2024 (USD Million)
3.4 Others
3.4.1 Other molecular diagnostic products market, 2013 - 2024 (USD Million)
Chapter 4 Europe Molecular Diagnostics Test Location Outlook
4.1 Molecular Diagnostics Revenue Share, by Test Location, 2013 & 2024
4.2 Molecular Diagnostic Point of Care Market
4.2.1 Molecular diagnosticspoint of care market, 2013 - 2024 (USD Million)
4.3 Molecular Diagnostics Self-Test or OTC Market
4.3.1 Self-Test or OTC molecular diagnostics market, 2013 - 2024 (USD Million)
4.4 Molecular Diagnostic Central Laboratories Market
4.4.1 Molecular diagnostic central laboratories market, 2013 - 2024 (USD Million)
Chapter 5 Europe Molecular Diagnostics Application Outlook
5.1 Molecular Diagnostics Revenue Share, by Application, 2013 & 2024
5.2 Molecular Diagnostics-based Infectious Diseases Market
5.2.1 Molecular diagnostics-based infectious diseasesmarket, 2013 - 2024 (USD Million)
5.3 Molecular Diagnostics-based Genetic Testing Market
5.3.1 Molecular diagnostics-based genetic testing market, 2013 - 2024 (USD Million)
5.4 Molecular Diagnostics-based Oncology Market
5.4.1 Molecular diagnostics-based oncology market, 2013 - 2024 (USD Million)
5.5 Molecular Diagnostic-based Pharmacogenomics Market
5.5.1 Molecular diagnostics-based Pharmacogenomics market, 2013 - 2024 (USD Million)
5.6 Molecular Diagnostics-based Cardiovascular Diseases Market
5.6.1 Molecular diagnostics-basedcardiovascular diseases market, 2013 - 2024 (USD Million)
5.7 Molecular Diagnostics-based Neurological Diseases Market
5.7.1 Molecular diagnostics-basedneurological diseases market, 2013 - 2024 (USD Million)
5.8 Molecular Diagnostics in Other Application Segments Market
5.8.1 Molecular Diagnostics in other application segments, 2013 - 2024 (USD Million)
Chapter 6 Europe Molecular Diagnostics Technology Outlook
6.1 Molecular Diagnostics Revenue Share by Technology, 2013 &2013 & 2024
6.2 Molecular Diagnostics Polymerase Chain Reaction (PCR) Market
6.2.1 Molecular diagnostics PCR Market, 2013 - 2024 (USD Million)
6.2.2 Multiplex PCR-based molecular diagnostics market
6.3 Molecular Diagnostics Transcription-mediated Amplification (TMA) Market
6.3.1 Molecular diagnostics TMA Market, 2013 - 2024 (USD Million)
6.4 Molecular Diagnostics In-situ Hybridization Market
6.4.1 Molecular diagnostic in-situ hybridization market, 2013 - 2024 (USD Million)
6.5 Molecular Diagnostic Sequencing Market
6.5.1 Molecular diagnostic sequencing market, 2013 - 2024 (USD Million)
6.6 Molecular Diagnostics Chips and Microarrays Market
6.6.1 Molecular Diagnostics Chips and Microarrays Market, 2013 - 2024 (USD Million)
6.7 Molecular Diagnostics Mass Spectrometry (MS) Market
6.7.1 Molecular diagnostics MSmarket, 2013 - 2024 (USD Million)
6.8 Molecular Diagnostic Other Technology Segments Market
6.8.1 Molecular diagnostic other technology segments market, 2013 - 2024 (USD Million)
Chapter 7 Europe Molecular Diagnostics Regional Outlook
7.1 Europe Molecular Diagnostics Revenue Share by Region, 2013 &2013 & 2024
7.2 UK
7.2.1 UK molecular diagnosticsmarket, 2013 - 2024 (USD Million)
7.3 Germany
7.3.1 Germany molecular diagnostics market, 2013 - 2024 (USD Million)
7.4 France
7.4.1 France molecular diagnostics market, 2013 - 2024 (USD Million)
7.5 Italy
7.5.1 Italy molecular diagnostics market, 2013 - 2024 (USD Million)
7.6 Spain
7.6.1 Spain molecular diagnostics market, 2013 - 2024 (USD Million)
7.7 Belgium
7.7.1 Belgium molecular diagnostics market, 2013 - 2024 (USD Million)
7.8 Switzerland
7.8.1 Switzerland molecular diagnostics market, 2013 - 2024 (USD Million)
7.9 Netherlands
7.9.1 Netherlands molecular diagnostics market, 2013 - 2024 (USD Million)
7.10 Poland
7.10.1 Poland molecular diagnostics market, 2013 - 2024 (USD Million)
7.11 Austria
7.11.1 Austria molecular diagnostics market, 2013 - 2024 (USD Million)
7.12 Greece
7.12.1 Greece molecular diagnostics market, 2013 - 2024 (USD Million)
7.13 Sweden
7.13.1 Sweden molecular diagnostics market, 2013 - 2024 (USD Million)
7.14 Turkey
7.14.1 Turkey molecular diagnostics market, 2013 - 2024 (USD Million)
7.15 Finland
7.15.1 Finland molecular diagnostics market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 Alere, Inc.
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Bayer Healthcare
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Becton, Dickinson and Company
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 bioMerieux
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Bio-Rad Laboratories, Inc.‏
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 Cepheid
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Dako
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 Danaher Corporation
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Hologic, Inc. (Gen Probe)
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
8.11 Johnson & Johnson
8.11.1 Company overview
8.11.2 Financial performance
8.11.3 Product benchmarking
8.11.4 Strategic initiatives
8.12 Novartis AG (Grifols)
8.12.1 Company overview
8.12.2 Financial performance
8.12.3 Product benchmarking
8.12.4 Strategic initiatives
8.13 Qiagen N.V.
8.13.1 Company overview
8.13.2 Financial performance
8.13.3 Product benchmarking
8.13.4 Strategic initiatives
8.14 Roche Diagnostics
8.14.1 Company overview
8.14.2 Financial performance
8.14.3 Product benchmarking
8.14.4 Strategic initiatives
8.15 Siemens Healthcare GmbH
8.15.1 Company overview
8.15.2 Financial performance
8.15.3 Product benchmarking
8.15.4 Strategic initiatives
8.16 Sysmex Corporation
8.16.1 Company overview
8.16.2 Financial performance
8.16.3 Product benchmarking
8.16.4 Strategic initiatives
Chapter 9 Methodology and Scope
9.1 Research Methodology
9.2 Research Scope & Assumptions
9.3 List of Data Sources
List of Tables
TABLE 1 Europe Molecular Diagnostics Market Driver Analysis
TABLE 2 Europe Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 3 Europe Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 4 Europe Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 5 Europe PCR market, by segments, 2013 - 2024 (USD Million)
TABLE 6 Europe Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 7 Europe oncology market, by application, 2013 - 2024 (USD Million)
TABLE 8 Europe Infectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 9 Europe Genetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 10 UK Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 11 UK Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 12 UK Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 13 UKPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 14 UK Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 15 UK oncology market, by application, 2013 - 2024 (USD Million)
TABLE 16 UKInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 17 UKGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 18 Germany Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 19 Germany Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 20 Germany Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 21 GermanyPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 22 Germany Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 23 Germany oncology market, by application, 2013 - 2024 (USD Million)
TABLE 24 GermanyInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 25 GermanyGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 26 France Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 27 France Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 28 France Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 29 FrancePCR market, by segments, 2013 - 2024 (USD Million)
TABLE 30 France Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 31 France oncology market, by application, 2013 - 2024 (USD Million)
TABLE 32 FranceInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 33 FranceGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 34 Spain Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 35 Spain Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 36 Spain Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 37 SpainPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 38 Spain Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 39 Spain oncology market, by application, 2013 - 2024 (USD Million)
TABLE 40 SpainInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 41 SpainGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 42 Italy Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 43 Italy Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 44 Italy Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 45 ItalyPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 46 Italy Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 47 Italy oncology market, by application, 2013 - 2024 (USD Million)
TABLE 48 ItalyInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 49 ItalyGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 50 Belgium Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 51 Belgium Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 52 Belgium Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 53 BelgiumPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 54 Belgium Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 55 Belgium oncology market, by application, 2013 - 2024 (USD Million)
TABLE 56 BelgiumInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 57 BelgiumGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 58 Switzerland Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 59 Switzerland Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 60 Switzerland Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 61 SwitzerlandPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 62 Switzerland Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 63 Switzerland oncology market, by application, 2013 - 2024 (USD Million)
TABLE 64 SwitzerlandInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 65 SwitzerlandGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 66 Netherlands Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 67 Netherlands Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 68 Netherlands Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 69 NetherlandsPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 70 Netherlands Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 71 Netherlands oncology market, by application, 2013 - 2024 (USD Million)
TABLE 72 NetherlandsInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 73 NetherlandsGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 74 Poland Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 75 Poland Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 76 Poland Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 77 PolandPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 78 Poland Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 79 Poland oncology market, by application, 2013 - 2024 (USD Million)
TABLE 80 PolandInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 81 PolandGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 82 Austria Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 83 Austria Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 84 Austria Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 85 AustriaPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 86 Austria Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 87 Austria oncology market, by application, 2013 - 2024 (USD Million)
TABLE 88 AustriaInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 89 AustriaGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 90 Greece Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 91 Greece Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 92 Greece Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 93 GreecePCR market, by segments, 2013 - 2024 (USD Million)
TABLE 94 Greece Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 95 Greece oncology market, by application, 2013 - 2024 (USD Million)
TABLE 96 GreeceInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 97 GreeceGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 98 Sweden Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 99 Sweden Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 100 Sweden Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 101 SwedenPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 102 Sweden Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 103 Sweden oncology market, by application, 2013 - 2024 (USD Million)
TABLE 104 SwedenInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 105 SwedenGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 106 Turkey Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 107 Turkey Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 108 Turkey Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 109 TurkeyPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 110 Turkey Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 111 Turkey oncology market, by application, 2013 - 2024 (USD Million)
TABLE 112 TurkeyInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 113 TurkeyGenetic testing market, by application, 2013 - 2024 (USD Million)
TABLE 114 Finland Molecular diagnostics market, by product, 2013 - 2024 (USD Million)
TABLE 115 Finland Molecular diagnostics market, by test location, 2013 - 2024 (USD Million)
TABLE 116 Finland Molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 117 FinlandPCR market, by segments, 2013 - 2024 (USD Million)
TABLE 118 Finland Molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 119 Finland oncology market, by application, 2013 - 2024 (USD Million)
TABLE 120 FinlandInfectious disease market, by application, 2013 - 2024 (USD Million)
TABLE 121 FinlandGenetic testing market, by application, 2013 - 2024 (USD Million)
List of Figures
FIG.1 Market summary
FIG.2 Market trends & outlook
FIG.3 Market segmentation & scope
FIG.4 Market driver relevance analysis (Current & future impact)
FIG.5 Penetration & growth prospect mapping
FIG.6 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG.7 Porter’s Five Forces Analysis
FIG.8 Global percentage of population, by age group, 2000 and 2050
FIG.9 General Trend of CLIA Waived Tests
FIG.10 Average selling price range of diagnostic tests, 2013
FIG.11 Company market share analysis - molecular diagnostics market, 2013
FIG.12 Recommendations for market participants
FIG.13 Europe Molecular Diagnostics market product outlook key takeaways
FIG.14 Europe Molecular Diagnostics market:product movement analysis
FIG.15 Europe instruments market, 2013 - 2024 (USD Million)
FIG.16 Europe reagents market, 2013 - 2024 (USD Million)
FIG.17 Other products market, 2013 - 2024 (USD Million)
FIG.18 Europe Molecular Diagnostics market test location outlook key takeaways
FIG.19 Europe Molecular Diagnostics market:test location movement analysis
FIG.20 Europe point of care market, 2013 - 2024 (USD Million)
FIG.21 Europeself test or OTC market, 2013 - 2024 (USD Million)
FIG.22 Central laboratories market, 2013 - 2024 (USD Million)
FIG.23 Europe Molecular Diagnostics market test location outlook key takeaways
FIG.24 Europe Molecular Diagnostics market:test location movement analysis
FIG.25 Europe point of care market, 2013 - 2024 (USD Million)
FIG.26 Europeself test or OTC market, 2013 - 2024 (USD Million)
FIG.27 Europe Molecular Diagnostics market technology outlook key takeaways
FIG.28 Europe Molecular Diagnostics market:technology movement analysis
FIG.29 Europe PCR Market, 2013 - 2024 (USD Million)
FIG.30 Europe Multiplex PCR market, 2013 - 2024 (USD Million)
FIG.31 Europe Other PCR market, 2013 - 2024 (USD Million)
FIG.32 Europe in-situ hybridization market, 2013 - 2024 (USD Million)
FIG.33 Europe INAAT market, 2013 - 2024 (USD Million)
FIG.34 Europe chips and microarrays market, 2013 - 2024 (USD Million
FIG.35 Europe MS market, 2013 - 2024 (USD Million)
FIG.36 Europe molecular diagnostic sequencing market, 2013 - 2024 (USD Million)
FIG.37 Europe TMA Market, 2013 - 2024 (USD Million)
FIG.38 Europe Others market, 2013 - 2024 (USD Million)
FIG.39 Europe Molecular Diagnostics market application outlook key takeaways
FIG.40 Europe Molecular Diagnostics market:application movement analysis
FIG.41 Europe oncology market, 2013 - 2024 (USD Million)
FIG.42 Europe Breast Cancer market, 2013 - 2024 (USD Million)
FIG.43 Europe Prostate Cancer market, 2013 - 2024 (USD Million)
FIG.44 Europe Colorectal Cancer market, 2013 - 2024 (USD Million)
FIG.44 Europe Cervical Cancer market, 2013 - 2024 (USD Million)
FIG.45 Europe Kidney Cancer market, 2013 - 2024 (USD Million)
FIG.46 Europe Liver Cancer market, 2013 - 2024 (USD Million)
FIG.47 Europe Blood Cancer market, 2013 - 2024 (USD Million)
FIG.48 Europe Lung Cancer market, 2013 - 2024 (USD Million)
FIG.49 Europe Other market, 2013 - 2024 (USD Million)
FIG.50 Europe pharmacogenomics market, 2013 - 2024 (USD Million)
FIG.51 Europe infectious disease market, 2013 - 2024 (USD Million)
FIG.52 Europe MRSA market, 2013 - 2024 (USD Million)
FIG.53 Europe Clostridium difficile market, 2013 - 2024 (USD Million)
FIG.54 Europe Vancomycin-resistant enterococci market, 2013 - 2024 (USD Million)
FIG.55 Europe Carbapenem-resistant market, 2013 - 2024 (USD Million)
FIG.56 EuropeFlu market, 2013 - 2024 (USD Million)
FIG.57 Europe Respiratory syncytial virus (RSV) market, 2013 - 2024 (USD Million)
FIG.58 Europe Candida market, 2013 - 2024 (USD Million)
FIG.59 Europe Tuberculosis and drug-resistant TB market, 2013 - 2024 (USD Million)
FIG.60 Europe Meningitis market, 2013 - 2024 (USD Million)
FIG.61 Europe Gastro-intestinal panel testing market, 2013 - 2024 (USD Million)
FIG.62 EuropeChlamydia market, 2013 - 2024 (USD Million)
FIG.63 Europe Gonorrhea market, 2013 - 2024 (USD Million)
FIG.64 Europe HIV market, 2013 - 2024 (USD Million)
FIG.65 Europe Hepatitis C market, 2013 - 2024 (USD Million)
FIG.66 EuropeHepatitis B market, 2013 - 2024 (USD Million)
FIG.67 Europe Other market, 2013 - 2024 (USD Million)
FIG.68 Europe genetic testing market, 2013 - 2024 (USD Million)
FIG.69 Europe Newborn screening market, 2013 - 2024 (USD Million)
FIG.70 Europe Predictive and presymptomatic testing market, 2013 - 2024 (USD Million)
FIG.71 Europe Others market, 2013 - 2024 (USD Million)
FIG.72 Europe neurological diseases market, 2013 - 2024 (USD Million)
FIG.73 Europe cardiovascular diseases market, 2013 - 2024 (USD Million)
FIG.74 Europe Microbiology market, 2013 - 2024 (USD Million)
FIG.75 Europe others market 2013 - 2024 (USD Million)
FIG.76 Europe Molecular Diagnostics market country outlook key takeaways
FIG.77 Europe Molecular Diagnostics market:country movement analysis
FIG.78 UKmolecular diagnostics market, 2013 - 2024 (USD Million)
FIG.79 Germanymolecular diagnostics market, 2013 - 2024 (USD Million)
FIG.80 Italymolecular diagnostics market, 2013 - 2024 (USD Million)
FIG.81 Spainmolecular diagnostics market, 2013 - 2024 (USD Million)
FIG.82 Belgium moleculardiagnostics market, 2013 - 2024 (USD Million)
FIG.83 Switzerland moleculardiagnostics market, 2013 - 2024 (USD Million)
FIG.84 Netherlands molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.85 Poland molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.86 Austria molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.87 Greece molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.88 Sweden moleculardiagnostics market, 2013 - 2024 (USD Million)
FIG.89 Turkey molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.90 Finland molecular diagnostics market, 2013 - 2024 (USD Million)
FIG.91 Strategy framework
FIG.92 Participant categorization

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report